Cuprina Holdings, a company focused on the development of treatments for myiasis (flystrike) in livestock, announced on May 30, 2026, the completion of a reverse stock split of its ordinary shares. The company also requested a hearing before the Nasdaq Hearings Panel to appeal a potential delisting and maintain its listing on the Nasdaq Capital Market.
The reverse stock split was approved by the company's board of directors and shareholders, aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement of $1.00. The exact ratio of the reverse stock split was not disclosed in the announcement, but such moves are common for companies facing compliance issues.
Cuprina Holdings has been working to regain compliance with Nasdaq's continued listing standards. The company's request for a hearing with the Nasdaq Hearings Panel is a procedural step to present its plan for regaining compliance and to stay any suspension of trading pending the panel's decision.
As of the latest filing, Cuprina Holdings had not yet reported financial results for the first quarter of 2026. The company's stock has faced volatility, and the reverse stock split is part of a broader strategy to stabilize its market position and attract investors.
Investors should note that reverse stock splits do not change the overall value of a shareholder's investment but can affect liquidity and market perception. Cuprina Holdings continues to focus on its core business of developing veterinary products for the global livestock industry.
